| Literature DB >> 30850034 |
Stephanie von Csiky-Sessoms1, Mark Lebwohl2.
Abstract
Psoriasis is a common, chronic inflammatory skin disease that is characterized by the formation of sharply demarcated, scaly, erythematous plaques. It affects about 2.2% of the population in the United States and has a large impact on patient quality of life. Many advances have been made in the last few years in the management of psoriasis. Proinflammatory cytokines play major roles in the pathogenesis of disease. Biologic medications targeting the aforementioned cytokines have been developed and studied for the management of psoriatic disease. This article summarizes the newest findings in the management of psoriasis and the various treatment options available.Entities:
Keywords: Biologic; Interleukin-17; Interleukin-23; Psoriasis; TNF-α; Treatment
Mesh：
Substances：
Year: 2019 PMID： 30850034 DOI： 10.1016/j.det.2018.11.001
Source DB: PubMed Journal: Dermatol Clin ISSN： 0733-8635 Impact factor: 3.478